Last updated: July 7, 2026
Persion Competitive Landscape Analysis: Market Position, Patent Strength, and Strategic Options
Persion’s competitive outlook is driven by (1) how its portfolio appears in the FDA Orange Book, (2) how long exclusivities (NCE, pediatric, 505(b)(2/ANDA exclusivity where applicable) extend, and (3) whether there are enforceable method-of-use or formulation patents that survive generic or 505(b)(2 entry. Without an identifiable active ingredient and FDA product identifier for “Persion,” a complete, accurate analysis cannot be produced.
What patents protect Persion (active ingredient) and who owns them?
A patent-protection map requires the marketed drug’s exact active ingredient, dosage form, and FDA application (NDA/BLA/505(b)(2)). Patent coverage differs materially by salt form, strength, route, and whether the portfolio is based on a new chemical entity versus an approved formulation or a new use.
How many Persion patents are listed in the Orange Book and by patent type?
Orange Book listings must be pulled for each strength and dosage form and then categorized by:
- Drug substance patents
- Drug product/formulation patents
- Method-of-use patents
- Manufacturing/process patents (where listed)
- Exclusivity codes tied to approval history
Which assignees hold the key Persion estate for enforceability?
Enforceability depends on correct assignee mapping across:
- Patent prosecution chains
- Ownership at the time of listing
- Maintenance and potential terminal disclaimer effects
- Prior art and claim scope around the marketed label
When does Persion lose exclusivity, and what dates control generic entry?
Exclusivity timing must be anchored to:
- Approval date of the original application
- Whether the active ingredient is an NCE
- Whether pediatric exclusivity applies
- 180-day exclusivity triggers tied to first Paragraph IV filer(s)
What is the earliest possible ANDA filing date for Persion?
Generic timing turns on:
- 30-month stay mechanics after a Paragraph IV notice (if applicable)
- Whether exclusivity has been carved out by later supplements
- Whether the reference listed drug (RLD) changes during life-cycle events
When do Orange Book patents expire for Persion by territory (US only vs. global strategy)?
A credible competitive calendar also needs patent family coverage beyond US for real-world strategy. That requires:
- Patent family mapping for the US granted set
- International filings (EP/WO/JP/CN equivalents)
- Likely enforcement jurisdictions based on distribution and launch plans
What patent litigation affects Persion, including Paragraph IV challenges and settlements?
Patent litigation is the strongest determinant of “real” entry timing.
Are there Persion Paragraph IV notices and which companies filed?
To analyze entry risk, you must identify:
- Each Paragraph IV ANDA (and its applicant)
- The asserted patents (Orange Book patent numbers)
- Litigation docket outcomes
- Whether settlements include “in-scope”/“carve-out” terms or delayed launch dates
What settlement terms typically govern Persion generic launch dates?
Settlement structures to map include:
- Triggered launch calendars tied to dismissal or covenant not to sue
- “Design-around” commitments (formulation or indication carve-outs)
- Forfeiture or payment terms tied to exclusivity and patent validity outcomes
What is the Orange Book status of Persion and how many listed patents block generics?
Orange Book analysis requires:
- Number of listed patents per dosage form/strength
- Status codes (expired, terminated, withdrawn, active)
- Patent expiration dates and whether they align with application supplements
Which Persion strengths and dosage forms have the highest generic blocking risk?
High-blocking risk usually concentrates where:
- Multiple method-of-use patents overlap labeled indications
- Formulation patents cover the exact commercial dosage form
- Process patents are necessary for bioavailability or stability
How does Persion compare with competing drugs in the same therapeutic class (US market structure)?
A full competitive landscape requires:
- Class-level comparator set (same MOA, similar indication scope, same line-of-therapy)
- Market share by formulary position (preferred vs. non-preferred)
- Net price and payer coverage, if available
- Clinical differentiation mapped to label and safety/monitoring endpoints
Which companies are challenging Persion in the US and with what regulatory pathways?
Competitive threat differs by pathway:
- ANDA for generics (same active, same RLD)
- 505(b)(2) for modified route/delivery or new formulation
- Biosimilar pathways apply only if Persion is a biologic (BLA)
What product attributes most affect substitutability for Persion?
Substitutability is shaped by:
- Route and dosing frequency
- Therapeutic drug monitoring requirements
- Bioavailability differences tied to formulation
- Switching constraints in clinical practice
What formulations are protected for Persion, and what “design-around” options exist?
Formulation and delivery system patents define whether entrants can launch “at risk” or must seek carve-outs.
Are Persion formulation patents tied to particle size, polymorph, coatings, or release profile?
Formulation claim scope can hinge on:
- Specific excipient ranges
- Controlled-release or extended-release architecture
- Solid-state form requirements (polymorph/hydrate)
- Stability and shelf-life constraints
What generic entry risks exist for Persion due to formulation constraints?
Entry risk rises when:
- Claims are specific to the marketed dosage form geometry
- Bioequivalence requires bridging that depends on the patented formulation
- Entrants cannot demonstrate non-infringement without changing core formulation
What method-of-use patents protect Persion’s indications and dosing regimens?
If the label contains multiple indications, method-of-use patents can fragment exclusivity.
Which indications for Persion are most protected by use patents?
Use-patent coverage can be strongest where claims track:
- Patient subsets (biomarker-defined populations)
- Combined regimens with other therapies
- Specific dose titration and escalation steps
- Duration and monitoring protocols
Do method-of-use patents create launch sequencing constraints for generics?
A generic may enter one indication while staying off-label for others if:
- The Paragraph IV challenge does not cover all asserted method-of-use claims
- Label carve-outs are enforced by settlement or injunction
Is Persion at risk for biosimilar entry or only generic competition?
This section applies only if Persion is a biologic with BLA and a biosimilar development footprint.
What biosimilar pathways apply to Persion?
If Persion is a biologic, analysis must cover:
- Reference product designation (BLA holder)
- Exclusivity rules under the BPCIA framework
- Patent disputes typically arising over use and manufacturing patents
What FDA regulatory status does Persion have and what milestones matter for competition?
Competition timing depends on regulatory history.
What is Persion’s RLD and approval history (NDA/BLA, supplements, and exclusivity codes)?
Regulatory milestones that affect entry:
- Original approval date
- Supplement approvals changing formulation, indications, or dosing
- REMS changes (where applicable)
- Safety label updates that can force new bridging and affect switching
Are there pending Persion changes that could extend patent or exclusivity coverage?
Life-cycle events that can shift competitive timelines include:
- New indications or line extensions
- New strengths or dosage forms
- Pediatric studies extensions tied to labeling changes
Commercial positioning: what is Persion’s market position, revenue exposure, and bargaining leverage?
A commercial landscape must quantify:
- US sales and net revenue trend
- Share by geography and payer segment
- Sales concentration by indication
- Contracting leverage in formulary negotiations
What revenue exposure is most sensitive to generic entry?
Exposure is highest where:
- The product is first-line and entrenched in standard of care
- Reimbursement is aligned to the branded label with limited payer flexibility
- Patient switching restrictions do not exist or are weak
How strong is Persion’s patent estate relative to its top competitors?
Estate strength compares:
- Number of active Orange Book patents
- Remaining time to expiration (weighted by asserted coverage)
- Frequency of successful Paragraph IV outcomes against similar estates
How does Persion’s patent estate compare with key competitors’ estates?
Competitive patent strength analysis requires mapping:
- Competitor RLDs and their listed patent counts
- Their remaining expiration calendars
- Their litigation histories and average settlement lead times
Which competitors have recently launched and how did litigation shape entry timing?
This identifies patterns that predict Persion’s path:
- Typical settlement durations
- How often courts invalidate key method-of-use or formulation claims
- Whether generic entry leads to substantial market share erosion
Key takeaways for strategy, licensing, and entry planning
- The decisive inputs for Persion’s competitive timeline are the Orange Book patent list (active status and expiration dates) and any Paragraph IV litigation history.
- The highest generic entry barriers usually come from overlapping method-of-use patents and formulation constraints that prevent straightforward “design-around” launches.
- Settlement terms and injunction outcomes drive “effective launch dates” more than nominal patent expiration.
FAQs
- How do Orange Book patent expiration dates differ from regulatory exclusivity for the same Persion product?
- What is the practical impact of method-of-use patent carve-outs on Persion generic label design?
- How do 30-month stays and pediatric exclusivity interact when multiple Persion patents are challenged?
- What formulation claim elements most often block generic “at-risk” launches for branded oral drugs like Persion?
- How should a competitor value Persion’s remaining active patent count versus time-to-expiration for investment decisions?
References
- US FDA. “Drugs@FDA: FDA Approved Drug Products.” U.S. Food and Drug Administration.
- US FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
- US FDA. “Paragraph IV Certifications and 180-Day Exclusivity.” U.S. Food and Drug Administration.
